Physician profile
Melissa E Cooper
NPI 1033193065
$1,034.84
in general payments reported to CMS, 2019-2025
18 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $824 · 2024: $21.22 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.07 | 2023-2025 | |
| Inspire Medical Systems, INC. | $144.14 | 2023 | Inspire |
| Horizon Therapeutics Plc | $99.48 | 2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $95.10 | 2023 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.64 | 2023 | Tradjenta, Glyxambi, Jardiance |
| Amgen INC. | $69.82 | 2023 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $39.12 | 2023 | |
| Organon LLC | $35.70 | 2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $31.01 | 2023 | |
| Pfizer INC. | $29.54 | 2023 | |
| Novo Nordisk INC | $27.86 | 2023 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $26.69 | 2023 | Trelegy Ellipta |
| Boston Scientific Corporation | $25.01 | 2025 | General - Pain Management |
| Astellas Pharma US INC | $23.06 | 2023 | Veozah |
| Seqirus USA INC | $21.67 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $16.48 | 2023 | |
| Lilly USA, LLC | $13.90 | 2023 | Mounjaro, Trulicity |
| Dexcom, INC. | $13.55 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.